CD274 and head and neck squamous cell carcinoma: In fit patients with relapsed or refractory PD-L1-positive HNSCC, pembrolizumab as a monotherapy or in combination with chemotherapy has demonstrated comparable effectiveness in broad, unselected cohorts13,17.